research peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
=== Pregnancy and breastfeeding === Spironolactone can cross the placenta. It has been found in the breast milk of lactating mothers, but only very small amounts of spironolactone and its metabolite canrenone enter breast milk, and the amount received by an infant during breastfeeding (<0.5% of the mother's dose) is considered to be insignificant. A study found that spironolactone was not associated with teratogenicity in the offspring of rats. Because it is an antiandrogen, however, spironolactone could theoretically have the potential to cause feminization of male fetuses at sufficient doses. In accordance, a subsequent study found that partial feminization of the genitalia occurred in the male offspring of rats that received doses of spironolactone that were five times higher than those normally used in humans (200 mg/kg per day). Another study found permanent, dose-related reproductive tract abnormalities rat offspring of both sexes at lower doses (50 to 100 mg/kg per day). In practice however, although experience is limited, spironolactone has never been reported to cause observable feminization or any other congenital defects in humans. Among 31 human newborns exposed to spironolactone in the first trimester, no signs of any specific birth defects were seen. A case report described a woman who was prescribed spironolactone during pregnancy with triplets and delivered all three (one boy and two girls) healthy; no observable feminization occurred in the boy.
=== 2 May === Russian Defence Minister Sergei Shoigu said that Russian success in Ukraine would "largely depend on the timely replenishment of weapons". He said that the Russian army had the weapons that it needed for 2023, nevertheless he asked a rocket producer to double its manufacture of precision missiles.
The company was founded in Pittsburgh, Pennsylvania, in 1902 by Chester Garfield Fisher (1881–1965), originally called the "Scientific Materials Co.". After obtaining his degree in engineering at Western University of Pennsylvania (now University of Pittsburgh), C.G. Fisher purchased the stockroom of the Pittsburgh Testing Laboratory. Fisher became a supplier of lab equipment and reagents for the area's industrial research. Early products included microscopes, burets, pipettes, litmus, balances, colorimeters, dissecting kits, and anatomical models. The first catalog, the 400 page Scientific Materials Co. Catalog of Laboratory Apparatus & Supplies, was published in 1904. Fisher established an R&D lab at his company in 1915. Edwin Fisher, Chester's brother, developed the Meker-Fisher burner in 1921, an advancement on the design of the Bunsen burner. The company manufactured an electric-combustion furnace and combustion train for analyzing carbon levels in steel, and an electrically heated and thermostatically controlled bacteriological incubator. In 1925, the company purchased Montreal-based Scientific Supplies, Ltd. The same year, the company was renamed Fisher Scientific. In 1940, Fisher Scientific acquired the New York supply company Eimer & Amend, which was founded in 1851 by Bernard G. Amend. Aiken Fisher, Chester's oldest son, became president of the company in 1949. In 1955, Fisher established a chemical manufacturing facility in Fair Lawn, New Jersey. In 1957, the company purchased the New York–based medical apparatus supply company E. Machlett & Sons.
Basic hydrolysis of esters, known as saponification, is not an equilibrium process; a full equivalent of base is consumed in the reaction, which produces one equivalent of alcohol and one equivalent of a carboxylate salt. The saponification of esters of fatty acids is an industrially important process, used in the production of soap. Esterification is a reversible reaction. Esters undergo hydrolysis under acidic and basic conditions. Under acidic conditions, the reaction is the reverse reaction of the Fischer esterification. Under basic conditions, hydroxide acts as a nucleophile, while an alkoxide is the leaving group. This reaction, saponification, is the basis of soap making.
Sources: en.wikipedia.org
== Side effects == Myelosuppression, specifically neutropenia, leukopenia, anemia, and thrombocytopenia Diarrhea, nausea, vomiting, stomatitis, and constipation Increased susceptibility to infections Asthenia
Serotonin taken orally does not pass into the serotonergic pathways of the central nervous system, because it does not cross the blood–brain barrier. However, tryptophan and its metabolite 5-hydroxytryptophan (5-HTP), from which serotonin is synthesized, do cross the blood–brain barrier. These agents are available as dietary supplements and in various foods, and may be effective serotonergic agents. One product of serotonin breakdown is 5-hydroxyindoleacetic acid (5-HIAA), which is excreted in the urine. Serotonin and 5-HIAA are sometimes produced in excess amounts by certain tumors or cancers, and levels of these substances may be measured in the urine to test for these tumors.
==== Sustainable biotextiles ==== Biotextiles are used as an alternative to synthetic textiles to prevent and combat the excess amounts of water and waste pollution from the textile industry. Large brands such as Nike, Adidas, Hermes and Stella McCartney are starting to use biotextiles for some of their fashion collections. One solution created by sustainable textile companies such as Pangaia and Agraloop is denim made out of nettle and hemp plants. Nettle plants are a renewable, biodegradable resource that can be used to design nettle denim by mixing organic cotton and Himalayan nettle. Hemp is another plant that is being looked into as an alternative denim material by these two companies since it is more durable and only consumes about a tenth of the water needed for cotton. The company Collina Strada is developing another biotextile solution called rose sylk. Rose sylk is an organic, biodegradable cellulose fiber that is derived from the natural waste of rose stems and bushes. Collina Strada promotes upcycling and reuse of old textiles by using factories to turn Ghana's textile waste materials into insulation for coats and houses. A third solution involves clothing made from a pineapple based leather alternative, which is currently being used by major brands such as Nike, Hugo Boss and H&M. This pineapple leather alternative is made from cellulose fibers extracted from pineapple leaves and stalks.
Sources: en.wikipedia.org
==== Forensic applications ==== The GC-EI-MS is also used in forensic science. One example is the analysis of five local anesthetics in blood using headspace solid-phase microextraction (HS-SPME) and gas chromatography–mass spectrometry–electron impact ionization selected ion monitoring (GC–MS–EI-SIM). Local anesthesia is widely used but sometimes these drugs can cause medical accidents. In such cases an accurate, simple, and rapid method for the analysis of local anesthetics is required. GC-EI-MS was used in one case with an analysis time of 65 minutes and a sample size of approximately 0.2 g, a relatively small amount. Another application in forensic practice is the determination of date rape drugs (DRDs) in urine. These drugs are used to incapacitate victims and then rape or rob them. The analyses of these drugs are difficult due to the low concentrations in the body fluids and often a long time delay between the event and clinical examination. However, using GC-EI-MS allows a simple, sensitive and robust method for the identification, detection and quantification of 128 compounds of DRDs in urine.
== Mediated apoptosis == Once inside the target cell, granzyme B can cleave and activate initiator caspases 8 and 10, and executioner caspases 3 and 7 which trigger apoptosis. Caspase 7 is the most sensitive to granzyme B and caspases 3, 8, and 10 are only cleaved to intermediate fragments and need further cleavage for full activation. Granzyme B can also cleave BID leading to BAX/BAK oligomerisation and cytochrome c release from the mitochondria. Granzyme B can cleave ICAD leading to DNA fragmentation and the laddering pattern associated with apoptosis. Granzyme B has a potential of over 300 substrates and can cleave Mcl-1 in the outer mitochondrial membrane relieving its inhibition of Bim. Bim stimulates BAX/BAK oligomerisation, mitochondrial membrane permeability and apoptosis. Granzyme B can also cleave HAX1 (Hs-1 associated protein X-1) to facilitate mitochondria polarisation. Granzyme B can also generate a cytotoxic level of mitochondrial reactive oxygen species (ROS) to mediate cell death. The caspase independent pathways of cell death are thought to have arisen to overcome viruses that can inhibit caspases and prevent apoptosis.
=== eDP === Embedded DisplayPort (eDP) is a display panel interface standard for portable and embedded devices. It defines the signaling interface between graphics cards and integrated displays. The various revisions of eDP are based on existing DisplayPort standards. However, version numbers between the two standards are not interchangeable. For instance, eDP version 1.4 is based on DisplayPort 1.2, while eDP version 1.4a is based on DisplayPort 1.3. Unlike standard DisplayPort, the Embedded DisplayPort lacks backward compatibility. eDP 1.0 was adopted in December 2008. It included advanced power-saving features such as seamless refresh rate switching. Version 1.1 was approved in October 2009 followed by version 1.1a in November 2009. Version 1.2 was approved in May 2010 and includes DisplayPort 1.2 HBR2 data rates, 120 Hz sequential color monitors, and a new display panel control protocol that works through the AUX channel. Version 1.3 was published in February 2011; it includes a new optional Panel Self-Refresh (PSR) feature developed to save system power and further extend battery life in portable PC systems. PSR mode allows the GPU to enter a power saving state in between frame updates by including framebuffer memory in the display panel controller. Version 1.4 was released in February 2013; it reduces power consumption through partial-frame updates in PSR mode, regional backlight control, lower interface voltages, and additional link rates; the auxiliary channel supports multi-touch panel data to accommodate different form factors.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.